Title: Hemolysis and Platelet Activation during Continuous Flow 
Mechanical Circulatory Support (CF MCS)
[STUDY_ID_REMOVED]
Date: 2/10/2023
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
21. 
22. 
23. 
24. 
25. 
26. 
27. 
28. 
29. �UiH@i3j§■ 1 IRB NUMBER: 2016-7404
_,....,..,_ ....... IRB APPROVAL DATE: Cl211Glf.20l!9
Gladwin, M.T. and V. Sachdev, Cardiovascular abnormalities in sickle cell disease. 
Journal of the American College of Cardiology, 2012. 59(13): p. 1123-1133. 
Wang, G.-R., et al., Mechanism of platelet inhibition by nitric oxide: in vivo 
phosphorylation ofthromboxane receptor by cyclic GMP-dependent protein kinase. 
Proceedings of the National Academy of Sciences, 1998. 95(9): p. 4888-4893. 
Samama, C.M., et al., Inhibition of platelet aggregation by inhaled nitric oxide in 
patients with acute respirat01y distress syndrome. Anesthesiology, 1995. 83(1): p. 56-65.
Gries, A., et al., Inhaled nitric oxide inhibits human platelet aggregation, P-selectin 
expression, and fibrinogen binding in vitro and in vivo. Circulation, 1998. 97(15): p.
1481-1487. 
Villagra, J., et al., Platelet activation in patients with sickle disease, hemolysis-associated 
pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood,
2007. 110(6): p. 2166-2172. 
Halcox J., et al, The effect of sildenafil on human vascular function, platelet activation, 
and myocardial ischemia. J Am Coll Cardiol. 2002 Oct 2;40(7):1232-40. 
Furlan M. and B. Lamm.le, Haemolytic-uraemic syndrome and thrombotic 
thrombocytop enic purpura-new insights into underlying biochemical mechanisms. 
Nephrology Dialysis Transplantation, 2000. 15(8): p. 1112-1114. 
Ono, T., et al., Severe seconda,y deficiency ofvon Willebran dfactor-cleaving protease 
(ADAMTSl 3) in patients with sepsis-induced disseminated intravascular coagulation: its 
correlation with development of renal failure. Blood, 2006. 107(2): p. 528-534.
Stockschlaeder, M., R. Schneppenheim, and U. Budde, Update on von Willebrand factor 
mu/timers: focus on high-molecular-weight mu/timers and their role in hemostasis. Blood
Coagulation & Fibrinolysis, 2014. 25(3): p. 206-216. 
Zhang, X., et al., Mechanoenzymatic cleavage of the ultralarge vascular protein von 
Willebrandfactor. Science, 2009. 324(5932): p. 1330-1334.
Uriel, N., et al., Acquired von Willebrand syndrome after continuous-flow mechanical 
device support contributes to a high prevalence of bleeding during long-term support and 
at the time of transplantation. Journal of the American College of Cardiology, 2010.
56(15):p. 1207-1213 
Meyer, A.L., et al., Acquired von Willebrand syndrome in patients with a centrifugal or 
axial continuous flow left ventricular assist device. JACC: Herui Failme, 2014. 2(2): p.
141-145.
Lu, R.N., et al., Unconjugated bilirubin inhibits proteolytic cleavage ofvon Willebrand 
factor by ADAMTS13 protease. Journal of Thrombosis and Haemostasis, 2015.
Da, Q., et al., Free hemoglobin increases von Willebrand factor-mediated platelet 
adhesion in vitro: implications for circulatory devices. Blood, 2015. 126(20): p. 2338-
2341. 
Dobaczewski, M.P., et al., Can we use adenosine diphosphate (ADP) to study" aspirin 
resistance"? The Janus faces of ADP-triggered platelet aggregation. Phaimacological
Reports, 2008. 60(3): p. 361. 
Jesty, J. and D. Bluestein, Acetylated prothrombin as a substrate in the measurement of 
the procoagulant activity of platelets: elimination of the feedback activation of platelets 
by thrombin. Analytical biochemistiy, 1999.
272(1): p. 64-70. 
Valerio, L., et al. Shear-mediated platelet activation in patients implanted with 
continuous flow LVADs: A preliminary study utilizing the platelet activity state (PAS) 
assay. in 2015 37th Annual International Conference of the IEEE Engineering in 
Medicine and Biology Societv (EMBC). 2015. IEEE.
Kokame, K., et al., FRETS-VWF73, afirstfluorogenic substrate for ADAMTSl 3 assay. 
Britishjournal of haematology, 2005. 129(1): p. 93-100. 
11 